Targeted nanoparticulated drug delivery systems have gained much attention owing to their potential in elevating
anti-tumor effect and decreasing drug-originated side effects. In this contribution, a kind of dual glioma targeting delivery
system was developed through co-modification nanoparticles with interlukin-13 peptide (IL-13p) and RGD peptide
(IRNPs), in which IL-13p could target to IL13Rα2 on tumor cells and RGD could target to αvβ3 on neovasculature. The
model drug, docetaxel (DTX), could release from the unmodified nanoparticles (NPs) and IRNPs at a sustained manner.
In vitro, the uptake of IRNPs by C6 (a glioma cell line) cells was time- and concentration-dependent, which was significantly
higher than the uptake of NPs and single modified nanoparticles. After loading with DTX, IRNPs induced the highest
percentage of apoptotic cells. In vivo, DTX-loaded IRNPs induced obviously higher apoptosis of cells in glioma site.
These results indicated the dual modification could improve the cellular uptake as well as antitumor effect, which demonstrated
IRNPs were promising drug delivery systems for glioma targeting treatment.